| scholarly article | Q13442814 |
| P50 | author | Quentin J Sattentau | Q59822898 |
| P2093 | author name string | Christopher J A Duncan | |
| Torben Schiffner | |||
| P2860 | cites work | Efficient HIV-1 transmission from macrophages to T cells across transient virological synapses | Q44307172 |
| Multiple proviral integration events after virological synapse-mediated HIV-1 spread | Q44571430 | ||
| Follicular dendritic cells and human immunodeficiency virus infectivity | Q45080369 | ||
| Recruitment of HIV and its receptors to dendritic cell-T cell junctions | Q47563778 | ||
| Biofilm-like extracellular viral assemblies mediate HTLV-1 cell-to-cell transmission at virological synapses. | Q55239314 | ||
| Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies | Q57226425 | ||
| Antigp41 antibodies fail to block early events of virological synapses but inhibit HIV spread between T cells | Q58023483 | ||
| Neutralizing antibodies inhibit HIV-1 transfer from primary dendritic cells to autologous CD4 T lymphocytes | Q84943267 | ||
| Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ | Q21090535 | ||
| Structural mechanism of trimeric HIV-1 envelope glycoprotein activation | Q21131394 | ||
| High multiplicity HIV-1 cell-to-cell transmission from macrophages to CD4+ T cells limits antiretroviral efficacy | Q22242698 | ||
| HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse | Q22242967 | ||
| Avoiding the void: cell-to-cell spread of human viruses | Q22251022 | ||
| In vivo imaging of virological synapses | Q22251074 | ||
| Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy | Q22251085 | ||
| Endocytosis of HIV: anything goes | Q22251441 | ||
| Dimeric association and segmental variability in the structure of human CD4 | Q24324340 | ||
| Structural definition of a conserved neutralization epitope on HIV-1 gp120 | Q24655948 | ||
| Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1 | Q24670055 | ||
| Redefining the viral reservoirs that prevent HIV-1 eradication | Q26827255 | ||
| A Blueprint for HIV Vaccine Discovery | Q26829865 | ||
| Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure | Q27312441 | ||
| Siglec-1 is a novel dendritic cell receptor that mediates HIV-1 trans-infection through recognition of viral membrane gangliosides | Q27318429 | ||
| HIV traffics through a specialized, surface-accessible intracellular compartment during trans-infection of T cells by mature dendritic cells | Q27318551 | ||
| The regulated secretory pathway in CD4(+) T cells contributes to human immunodeficiency virus type-1 cell-to-cell spread at the virological synapse | Q27349077 | ||
| Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates | Q27629806 | ||
| Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design | Q27634018 | ||
| Antibody domain exchange is an immunological solution to carbohydrate cluster recognition | Q27641517 | ||
| Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 | Q27644478 | ||
| HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane | Q27649531 | ||
| Molecular architecture of native HIV-1 gp120 trimers | Q27651385 | ||
| Crystallographic Definition of the Epitope Promiscuity of the Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5: Vaccine Design Implications | Q27657377 | ||
| Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 | Q27663293 | ||
| A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield | Q27675032 | ||
| Broad and potent neutralization of HIV-1 by a gp41-specific human antibody | Q27675131 | ||
| Crystallographic structure of an intact IgG1 monoclonal antibody | Q27748871 | ||
| Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody | Q27759364 | ||
| UCSF Chimera--a visualization system for exploratory research and analysis | Q27860666 | ||
| DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells | Q28138968 | ||
| Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies | Q28602877 | ||
| Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target | Q29547347 | ||
| Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand | Q29547531 | ||
| Broad neutralization coverage of HIV by multiple highly potent antibodies | Q29615361 | ||
| Immune-correlates analysis of an HIV-1 vaccine efficacy trial | Q29617377 | ||
| Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody | Q29618366 | ||
| Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 | Q29619511 | ||
| Targeting early infection to prevent HIV-1 mucosal transmission. | Q30386549 | ||
| Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses | Q30480959 | ||
| Simultaneous cell-to-cell transmission of human immunodeficiency virus to multiple targets through polysynapses | Q30487819 | ||
| Quantitative 3D video microscopy of HIV transfer across T cell virological synapses | Q30490761 | ||
| Virological synapse-mediated spread of human immunodeficiency virus type 1 between T cells is sensitive to entry inhibition | Q30493649 | ||
| 3D visualization of HIV transfer at the virological synapse between dendritic cells and T cells | Q30496061 | ||
| Multiploid inheritance of HIV-1 during cell-to-cell infection | Q30501773 | ||
| Cell-to-cell transfer of HIV-1 via virological synapses leads to endosomal virion maturation that activates viral membrane fusion | Q30505286 | ||
| Macrophage internal HIV-1 is protected from neutralizing antibodies | Q30510067 | ||
| Neutralization resistance of virological synapse-mediated HIV-1 Infection is regulated by the gp41 cytoplasmic tail | Q30524110 | ||
| Antiretroviral agents effectively block HIV replication after cell-to-cell transfer | Q30524224 | ||
| In vitro derived dendritic cells trans-infect CD4 T cells primarily with surface-bound HIV-1 virions | Q33269795 | ||
| Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro | Q33853775 | ||
| Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. | Q34015978 | ||
| Maturation-induced cloaking of neutralization epitopes on HIV-1 particles | Q34023008 | ||
| Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies | Q34229664 | ||
| Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer | Q34292319 | ||
| The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. | Q34341843 | ||
| Cell-to-cell transmission can overcome multiple donor and target cell barriers imposed on cell-free HIV. | Q34544718 | ||
| Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody | Q34630446 | ||
| Dendritic Cells and HIV-1 Trans-Infection | Q34632997 | ||
| The infectious synapse formed between mature dendritic cells and CD4(+) T cells is independent of the presence of the HIV-1 envelope glycoprotein | Q34650563 | ||
| Redox-Triggered Infection by Disulfide-Shackled Human Immunodeficiency Virus Type 1 Pseudovirions | Q34977075 | ||
| Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L | Q35012462 | ||
| Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors | Q35382871 | ||
| Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages | Q35826158 | ||
| HIV cell-to-cell transmission requires the production of infectious virus particles and does not proceed through env-mediated fusion pores | Q35826780 | ||
| Transmembrane domain membrane proximal external region but not surface unit-directed broadly neutralizing HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 trans-infection | Q35842299 | ||
| PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. | Q35868102 | ||
| Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site | Q35943521 | ||
| Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape | Q36000736 | ||
| Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein | Q36131738 | ||
| HIV-infected T cells are migratory vehicles for viral dissemination | Q36315429 | ||
| Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo | Q36414891 | ||
| A fusion inhibitor prevents spread of immunodeficiency viruses, but not activation of virus-specific T cells, by dendritic cells. | Q36673272 | ||
| Broad HIV-1 neutralization mediated by CD4-binding site antibodies | Q36977635 | ||
| Development of prophylactic vaccines against HIV-1. | Q37042563 | ||
| Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm | Q37247974 | ||
| HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. | Q37259407 | ||
| Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection | Q37273158 | ||
| Cell-to-cell HIV-1 spread and its implications for immune evasion | Q37429751 | ||
| Infection of specific dendritic cells by CCR5-tropic human immunodeficiency virus type 1 promotes cell-mediated transmission of virus resistant to broadly neutralizing antibodies | Q37583414 | ||
| Virus cell-to-cell transmission. | Q37726587 | ||
| HIV-1 Virological Synapse is not Simply a Copycat of the Immunological Synapse | Q37796606 | ||
| Cell-to-Cell Spread of Retroviruses | Q37945208 | ||
| The HTLV-1 Virological Synapse. | Q38615502 | ||
| A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity. | Q39537121 | ||
| Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells. | Q39583017 | ||
| Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells | Q39700360 | ||
| Efficient capture of antibody neutralized HIV-1 by cells expressing DC-SIGN and transfer to CD4+ T lymphocytes | Q40168741 | ||
| Preparation and characterization of human HIV type 1 neutralizing reference sera | Q41332501 | ||
| Epitope exposure on functional, oligomeric HIV-1 gp41 molecules | Q41381359 | ||
| Generation of Human Monoclonal Antibodies against HIV-1 Proteins; Electrofusion and Epstein-Barr Virus Transformation for Peripheral Blood Lymphocyte Immortalization | Q41478638 | ||
| pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane | Q41764642 | ||
| Architecture and regulation of the HIV-1 assembly and holding compartment in macrophages | Q42140364 | ||
| Structural comparison of HIV-1 envelope spikes with and without the V1/V2 loop | Q42707235 | ||
| Adhesion molecule interactions facilitate human immunodeficiency virus type 1-induced virological synapse formation between T cells | Q42910380 | ||
| Inefficient human immunodeficiency virus replication in mobile lymphocytes | Q42957159 | ||
| Infection of macaques after vaginal exposure to cell-associated simian immunodeficiency virus | Q43009530 | ||
| P433 | issue | 49 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 5789-5797 | |
| P577 | publication date | 2013-10-17 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Cell-to-cell spread of HIV-1 and evasion of neutralizing antibodies | |
| P478 | volume | 31 |
| Q30596957 | A comparison of elasticities of viral levels to specific immune response mechanisms in human immunodeficiency virus infection. |
| Q34180174 | Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice |
| Q34262089 | Broadly neutralizing antibody VRC01 prevents HIV-1 transmission from plasmacytoid dendritic cells to CD4 T lymphocytes |
| Q35686912 | Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent |
| Q37182721 | Cell-Free versus Cell-to-Cell Infection by Human Immunodeficiency Virus Type 1 and Human T-Lymphotropic Virus Type 1: Exploring the Link among Viral Source, Viral Trafficking, and Viral Replication. |
| Q37347313 | Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppres |
| Q38231405 | DC-T cell virological synapses and the skin: novel perspectives in dermatology |
| Q38515936 | Dynamics of virus-receptor interactions in virus binding, signaling, and endocytosis |
| Q37154783 | Encoded novel forms of HSP70 or a cytolytic protein increase DNA vaccine potency |
| Q40794254 | Exploring the benefits of antibody immune response in HIV-1 infection using a discrete model. |
| Q60951107 | Gene Editing of HIV-1 Co-receptors to Prevent and/or Cure Virus Infection |
| Q27681313 | HIV Cell-to-Cell Spread Results in Earlier Onset of Viral Gene Expression by Multiple Infections per Cell |
| Q36269097 | HIV transmission biology: translation for HIV prevention |
| Q57030223 | HIV-1 cell-to-cell transmission and broadly neutralizing antibodies |
| Q30570557 | High-multiplicity HIV-1 infection and neutralizing antibody evasion mediated by the macrophage-T cell virological synapse. |
| Q37593177 | Identification of Human Anti-HIV gp160 Monoclonal Antibodies That Make Effective Immunotoxins |
| Q58724429 | Importance of Fc-mediated functions of anti-HIV-1 broadly neutralizing antibodies |
| Q35861276 | Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission |
| Q42638889 | Maternal but Not Infant Anti-HIV-1 Neutralizing Antibody Response Associates with Enhanced Transmission and Infant Morbidity |
| Q39578041 | Molecular Determinants Directing HIV-1 Gag Assembly to Virus-Containing Compartments in Primary Macrophages |
| Q40295939 | Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives |
| Q59358562 | Neutralizing Antibody-Based Prevention of Cell-Associated HIV-1 Infection |
| Q40312301 | New Connections: Cell-to-Cell HIV-1 Transmission, Resistance to Broadly Neutralizing Antibodies, and an Envelope Sorting Motif |
| Q35745453 | Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity |
| Q40088529 | Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection |
| Q34309493 | Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain's exceptional capacity for sequence variation |
| Q30754418 | Porcine Reproductive and Respiratory Syndrome Virus Utilizes Nanotubes for Intercellular Spread |
| Q100535027 | Preferential recognition and antagonism of SARS-CoV-2 spike glycoprotein binding to 3- O -sulfated heparan sulfate |
| Q58569712 | Recent progress in broadly neutralizing antibodies to HIV |
| Q36294727 | Short Communication: Exploring Antibody Potential as Prophylactic/Therapeutic Strategies for Prevention of Early Mucosal HIV-1 Infection |
| Q41924135 | T cell-macrophage fusion triggers multinucleated giant cell formation for HIV-1 spreading. |
| Q95602650 | TMPRSS2 and TMPRSS4 mediate SARS-CoV-2 infection of human small intestinal enterocytes |
| Q94670006 | TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes |
| Q37415455 | The Glycosylphosphatidylinositol-Anchored Variable Region of Llama Heavy Chain-Only Antibody JM4 Efficiently Blocks both Cell-Free and T Cell-T Cell Transmission of Human Immunodeficiency Virus Type 1. |
| Q92881205 | The Impact of Cellular Proliferation on the HIV-1 Reservoir |
| Q40190061 | The pentameric complex drives immunologically covert cell-cell transmission of wild-type human cytomegalovirus |
| Q41102793 | Vpr Promotes Macrophage-Dependent HIV-1 Infection of CD4+ T Lymphocytes |
| Q33772637 | Which Antibody Functions are Important for an HIV Vaccine? |
Search more.